技术与产品开发 - OmniUltra是首个在人体框架上生产超长CDRH3抗体的转基因鸡平台，具有独特的抗体结构和功能[24] - 超长CDRH3抗体能够到达其他抗体无法接触的结合口袋，具有潜在的临床应用[24] - OmniUltra平台可用于发现生物优化的结构肽，具有高亲和力和特异性[49] - 超长CDRH3抗体在多种治疗靶点上表现出免疫反应，显示出广泛的应用潜力[42] - OmniUltra平台的技术优势将推动新药的发现和开发，提高临床成功率[37] 市场前景 - 预计到2034年，相关的商业治疗市场总可用市场（TAM）将超过1万亿美元，其中肽类药物市场预计为3320亿美元[64] - 预计未来肽类治疗的全球销售将显著增长，市场潜力不断扩大[63] - 预计未来肽类药物将覆盖多种治疗领域，包括代谢、心脏病、感染性疾病和癌症[58] 合作与收入增长 - OmniUltra平台的开发将增加与超过130家肽类公司的合作机会，推动服务收入增长[68] - 2020年至2023年期间，FDA批准的肽类药物数量持续增加，显示出肽类药物的市场需求[56]

TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Table of Contents As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8731 98-1584818 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identif ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 98-1584818 (I.R.S. Employer Identifi ...